Biggest Investing Moment...
Man Who Called Tesla & Bitcoin: "Nobody is Paying Attention to This"
Click here to see what you are missing

SLN Insider Trading (Silence Therapeutics)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £19,977.80
Insider Selling (Last 12 Months): GBX 0

Silence Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Silence Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Silence Therapeutics Share Price & Price History

Current Price: GBX 536
Price Change: Price Increase of +1 (0.19%)
As of 09/24/2021 01:00 AM ET

This chart shows the closing price history over time for SLN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MarketBeat's Top 5 Stock Picks - Just Released
MarketBeat has just released five new trading ideas, but Tesla, Apple, and Netflix didn't make the cut. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. Now, MarketBeat thinks these five stocks may be even better buys.
View the Stocks Here

Silence Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/9/2020Giles CampionInsiderBuy4,945GBX 404£19,977.80
5/28/2020Iain RossInsiderBuy15,800GBX 470£74,260
5/11/2020Rob QuinnInsiderSell73,112GBX 398£290,985.76
5/7/2020Rob QuinnInsiderSell15,942GBX 429£68,391.18
10/4/2019Dave LemusInsiderBuy4,000GBX 186£7,440
10/2/2019Steven RomanoInsiderBuy10,000GBX 193£19,300
See Full Table
Insider Buying at Silence Therapeutics?
Sign-up to receive's daily insider buying and selling report for Silence Therapeutics and related companies.

SEC Filings (Institutional Ownership Changes) for Silence Therapeutics (LON:SLN)

Silence Therapeutics logo
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
Read More on Silence Therapeutics

Today's Range

Now: GBX 536
Low: 531
High: 564

50 Day Range

MA: GBX 581.16
Low: 525
High: 620

52 Week Range

Now: GBX 536
Low: 330
High: 680


2,531 shs

Average Volume

70,192 shs

Market Capitalization

£480.98 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Silence Therapeutics?

Silence Therapeutics' top insider shareholders include:
  1. Dave Lemus (Insider)
  2. Giles Campion (Insider)
  3. Iain Ross (Insider)
  4. Rob Quinn (Insider)
  5. Steven Romano (Insider)
The $7 Secret to $1,000 in Upfront Payouts
Extract $500... $1,000... even $1,500 in upfront payments from some of the market's hottest blue chip companies... without buying a single option.

It's unlike anything you've seen before, and it's never been more affordable to get started.
Click here for details.